<DOC>
	<DOCNO>NCT02002702</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study ass safety , tolerability pharmacokinetics explore efficacy IV infusion 10 µg/kg/day 30 µg/kg/day serelaxin 48 hour compare placebo , add standard therapy , approximately 45 Japanese AHF patient .</brief_summary>
	<brief_title>Study Safety , Tolerability Pharmacokinetics Serelaxin Japanese Acute Heart Failure ( AHF ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Key Written inform consent must obtain studyspecific assessment perform . Male female ≥20 year age , body weight ≥30 kg ≤160 kg Hospitalized AHF ; AHF define include following measure time presentation ( include emergency department ) end screening : Dyspnea rest minimal exertion Pulmonary congestion chest radiograph BNP ≥350 pg/mL NTproBNP ≥1,400 pg/mL SBP ≥125 mmHg start end screen Able randomize within 16 hour presentation hospital , include emergency department Received intravenous ( IV ) furosemide least 40 mg ( equivalent ) time presentation ( include outpatient clinic , ambulance , hospital include emergency department ) start screen study treatment current acute heart failure ( HF ) episode . Impaired renal function define estimate glomerular filtration rate ( eGFR ) presentation randomization ≥ 25 and≤ 75 mL/min/1.73 m2 , calculate use Japanese formula Key Dyspnea primarily due noncardiac cause Temperature &gt; 38.5°C ( oral equivalent ) sepsis active infection require IV antimicrobial treatment Clinical evidence acute coronary syndrome currently within 30 day prior enrollment . AHF due significant arrhythmia , include follow : sustain ventricular tachycardia , bradycardia sustain ventricular rate &lt; 45 beat per minute , atrial fibrillation/flutter sustain ventricular response &gt; 130 beat per minute .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Acute heart failure ( AHF ) ,</keyword>
	<keyword>Japanese ,</keyword>
	<keyword>Safety tolerability , Pharmacokinetics ,</keyword>
	<keyword>Renal Impairment</keyword>
</DOC>